IMPE Abstracts

Background: Osteogenesis imperfecta (OI) is a genetic connective tissue disorder with variable phenotype, mainly characterized by bone fragility, multiple fractures, bone deformities, short stature and non-skeleton findings like blue/gray scleras. The pharmacological approach for OI is based on the use of bisphosphonates to improve bone health. Since growth failure is a predominant feature of OI, recombinant human growth hormone (rhGH) treatment has been sugge...